RDY
NYSE
Pharmaceuticals
$11.38
USD
-$1.18 (-9.39%)
At close: Jul 22, 2026, 4:00 PM EDT
Market Cap:
$10.42B
Volume:
4.3M
Previous Close
$12.56
Day Range
$11.36 - $12.07
52 Week Range
$11.36 - $15.67
Average Volume (10 Days)
3.4M
P/E Ratio (TTM)
23.99
Dividend Yield
0.66%
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
CEO
Mr. Erez Israeli
Headquaters
Hyderabad, TELANGANA, IN
Founded
1986
Employees
27,527
Dr. Reddy's reported a 5.6% year-over-year revenue decline to INR 8,071 crores ($853 million) in Q1 FY27, with EBITDA margin falling to 12.5% due to semaglutide API-related challenges and lower lenalidomide sales. Excluding a INR 240 crore provision for semaglutide-related inventory and costs, EBITDA margin would have been 15.4%. Management said the base business excluding lenalidomide continued to grow at a double-digit rate.
0
0